ArticleFrontiers in pharmacology2025

A randomized, open-label, two-period crossover study to evaluate the bioequivalence and food effect between two formulations of regorafenib in healthy adult participants.

Yan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.